skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0

Abstract

This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and Trius Therapeutics, Inc. ("Trius") to develop novel agents for gram-negative biodefense pathogens. LLNL and Trius jointly responded to a U.S. Health and Human Services (National Institutes of Health) request for proposals (solicitation # BAA NIH-NIAID-DMID 08-20) to develop new therapeutic countermeasures with a proposal entitled "Development of Therapeutic Agents for Select Biodefense Pathogens" which resulted in this CRADA, with a goal of developing gram-negative, dual-target antibacterial agents that show no cross-resistance to existing drugs. Trius was awarded Contract HHSN272200800042C to accomplish the goals in the proposal, with LLNL as a major subcontractor.

Authors:
 [1];  [2];  [2]
  1. Trius Theraputics, San Diego, CA (United States)
  2. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Publication Date:
Research Org.:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1424632
Report Number(s):
LLNL-TR-745528
DOE Contract Number:  
AC52-07NA27344
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Finn, J., Lightstone, F., and Turteltaub, K. W. Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0. United States: N. p., 2018. Web. doi:10.2172/1424632.
Finn, J., Lightstone, F., & Turteltaub, K. W. Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0. United States. doi:10.2172/1424632.
Finn, J., Lightstone, F., and Turteltaub, K. W. Wed . "Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0". United States. doi:10.2172/1424632. https://www.osti.gov/servlets/purl/1424632.
@article{osti_1424632,
title = {Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0},
author = {Finn, J. and Lightstone, F. and Turteltaub, K. W.},
abstractNote = {This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and Trius Therapeutics, Inc. ("Trius") to develop novel agents for gram-negative biodefense pathogens. LLNL and Trius jointly responded to a U.S. Health and Human Services (National Institutes of Health) request for proposals (solicitation # BAA NIH-NIAID-DMID 08-20) to develop new therapeutic countermeasures with a proposal entitled "Development of Therapeutic Agents for Select Biodefense Pathogens" which resulted in this CRADA, with a goal of developing gram-negative, dual-target antibacterial agents that show no cross-resistance to existing drugs. Trius was awarded Contract HHSN272200800042C to accomplish the goals in the proposal, with LLNL as a major subcontractor.},
doi = {10.2172/1424632},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Wed Jan 31 00:00:00 EST 2018},
month = {Wed Jan 31 00:00:00 EST 2018}
}

Technical Report:

Save / Share: